NDAQ:ASND - Post Discussion
Post by
whytestocks on Sep 16, 2024 10:32am
Pivotal ApproaCH Trial of TransCon(TM) CNP (Navepegritide) A
JUST IN: $ASND Pivotal ApproaCH Trial of TransCon(TM) CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo–    TransCon CNP demonstrated AGV superior to placebo with LS mean treatment difference of 1.49 cm/year at Week 52 (p<0.0001) –    For children aged 5-11 years TransCon CNP demonstrated a change from baseline AGV superior to placebo with LS mea...
ASND - Pivotal ApproaCH Trial of TransCon(TM) CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo
Be the first to comment on this post